NASDAQ: IPHA
Innate Pharma Sa Stock

$1.70-0.04 (-2.3%)
Updated Jul 14, 2025
IPHA Price
$1.70
Fair Value Price
-$0.44
Market Cap
$142.51M
52 Week Low
$1.29
52 Week High
$3.51
P/E
-2.45x
P/B
14.2x
P/S
7.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.86M
Earnings
-$51.53M
Gross Margin
100%
Operating Margin
-226.11%
Profit Margin
-245.9%
Debt to Equity
11.57
Operating Cash Flow
-$7M
Beta
0.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IPHA Overview

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IPHA's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
IPHA
Ranked
Unranked of 475

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important IPHA news, forecast changes, insider trades & much more!

IPHA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IPHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IPHA ($1.70) is overvalued by 489.87% relative to our estimate of its Fair Value price of -$0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IPHA ($1.70) is not significantly undervalued (489.87%) relative to our estimate of its Fair Value price of -$0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IPHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IPHA due diligence checks available for Premium users.

Valuation

IPHA fair value

Fair Value of IPHA stock based on Discounted Cash Flow (DCF)

Price
$1.70
Fair Value
-$0.44
Undervalued by
489.87%
IPHA ($1.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IPHA ($1.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IPHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IPHA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.45x
Industry
-158.64x
Market
31.22x

IPHA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
14.2x
Industry
4.66x
IPHA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IPHA's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IPHA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IPHA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$115.7M
Liabilities
$106.5M
Debt to equity
11.57
IPHA's short-term assets ($97.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IPHA's short-term assets ($97.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IPHA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IPHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
IPHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IPHA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IPHA$142.51M-2.47%-2.45x14.20x
CGENC$142.37M0.00%-9.94x2.49x
LYELC$142.80M-0.82%-0.39x0.42x
ASMBC$143.89M+0.48%-3.02x5.30x
ELTXD$143.97M+11.39%-2.30x16.17x

Innate Pharma Sa Stock FAQ

What is Innate Pharma Sa's quote symbol?

(NASDAQ: IPHA) Innate Pharma Sa trades on the NASDAQ under the ticker symbol IPHA. Innate Pharma Sa stock quotes can also be displayed as NASDAQ: IPHA.

If you're new to stock investing, here's how to buy Innate Pharma Sa stock.

What is the 52 week high and low for Innate Pharma Sa (NASDAQ: IPHA)?

(NASDAQ: IPHA) Innate Pharma Sa's 52-week high was $3.51, and its 52-week low was $1.29. It is currently -51.58% from its 52-week high and 31.78% from its 52-week low.

How much is Innate Pharma Sa stock worth today?

(NASDAQ: IPHA) Innate Pharma Sa currently has 83,830,336 outstanding shares. With Innate Pharma Sa stock trading at $1.70 per share, the total value of Innate Pharma Sa stock (market capitalization) is $142.51M.

Innate Pharma Sa stock was originally listed at a price of $6.14 in Oct 18, 2019. If you had invested in Innate Pharma Sa stock at $6.14, your return over the last 5 years would have been -72.31%, for an annualized return of -22.65% (not including any dividends or dividend reinvestments).

How much is Innate Pharma Sa's stock price per share?

(NASDAQ: IPHA) Innate Pharma Sa stock price per share is $1.70 today (as of Jul 14, 2025).

What is Innate Pharma Sa's Market Cap?

(NASDAQ: IPHA) Innate Pharma Sa's market cap is $142.51M, as of Jul 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Innate Pharma Sa's market cap is calculated by multiplying IPHA's current stock price of $1.70 by IPHA's total outstanding shares of 83,830,336.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.